AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00830479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-reflux surgery
Description: Open ureteroneocystostomy for correction of vesicoureteral reflux
Study NCT00830479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic injection
Description: Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
Study NCT04557189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 SC injection
Study NCT04557189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron IV injection
Study NCT04557189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching IV injection
Study NCT04557189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951 Placebo
Description: TAK-951 placebo-matching SC injection
Study NCT03802045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
Study NCT01997827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metal-ceramic RBFDP
Description: Rehabilitation of tooth loss with a metal-ceramic RBFDP
Study NCT01997827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: all-ceramic RBFDP
Description: Rehabilitation of tooth loss with an all-ceramic RBFDP
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab IV
Description: Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
Study NCT01200758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
Study NCT01638546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01638546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01638546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01638546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT03335137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Drug Level Monitoring
Description: Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
Study NCT01554319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL.
Study NCT01554319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.
Study NCT04050215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04050215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT03802045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
Study NCT04050215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04050215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02461251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational Thromboelastometry (ROTEM)
Description: A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
Study NCT03802045 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Needle
Description: Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
Study NCT03802045 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Adhesive Moxa
Description: In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
Study NCT00910169 — intervention group
Intervention type: OTHER
Intervention: inpatient treatment
Description: Hospitalisation modalities are described but are naturalistic
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part A (SAD)
Description: Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
Study NCT02888548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
Description: orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
Study NCT00511823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casopitant
Description: The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part A (SAD)
Description: Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study NCT01801150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP nasal treatment
Description: Treatment with titred CPAP nasal during the nighttime
Study NCT02418195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
Study NCT01512953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg once a day
Study NCT01549964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam (TAK-875)
Description: Fasiglifam (TAK-875) tablets
Study NCT00511823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolasetron
Description: The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
Study NCT01675063 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Retia Non-Invasive Sensors
Description: Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
Study NCT01296100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (nutrition)
Description: The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
Study NCT01549964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin tablets
Study NCT01549964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets
Study NCT01969812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evie Slow-release Insemination Device
Study NCT01296100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity)
Description: The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
Study NCT01969812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Intrauterine Insemination
Study NCT01824186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILC
Description: Underwent single-incision laparoscopic cholecystectomy
Study NCT01525459 — intervention group
Intervention type: PROCEDURE
Intervention: Glioma resection
Description: Patients will be treated with the standard surgical therapy - glioma resection.
Study NCT01525459 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
Study NCT02771366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermented Papaya Preparation
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Study NCT02771366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Papaya Preparation
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Study NCT02771366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Granulated Sugar
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Study NCT02771366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Granulated Sugar
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Study NCT02776124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healing Elements,Methuselah Medical Technology
Description: ONS group will receive Healing Elements ONS everyday during CRT
Study NCT03528915 — intervention group
Intervention type: OTHER
Intervention: Rifamycine treatment
Description: Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
Study NCT03528915 — intervention group
Intervention type: OTHER
Intervention: whithout Rifamycine treatment
Description: Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
Study NCT02454556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLITIME®
Study NCT02454556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-F®
Study NCT02734394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cardiovascular and resistance exercise training
Study NCT02474004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medial meniscal surgery
Description: one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
Study NCT02474004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial meniscal surgery
Description: one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
Study NCT00680134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690
Description: AN2690 1% Solution, once daily for 180 days
Study NCT01638546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study NCT01638546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT00680134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690
Description: AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
Study NCT00671853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
Study NCT00671853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for quetiapine XR
Description: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
Study NCT02008214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Addition of pentoxifylline to current HCV treatment
Study NCT02008214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching pentoxifylline dosage
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part B (MAD)
Description: Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part B (MAD)
Description: Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part C (FE)
Description: Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part D (FE)
Description: Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-755 Part E (MAD)
Description: Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
Study NCT03414294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part E (MAD)
Description: Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Study NCT01371227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNS002
Description: 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
Study NCT00511823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
Study NCT04690244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan trainings
Description: 10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
Study NCT03313336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA test patch
Description: EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
Study NCT03313336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA current reference patch
Description: EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
Study NCT03313336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
Study NCT01705678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: Krill oil 300 mg DHA/EPA daily for 6 weeks
Study NCT01705678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil 500 mg DHA/EPA daily for 6 weeks
Study NCT05241145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED-80
Description: Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
Study NCT00511823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
Study NCT03778476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Exercise
Description: Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
Study NCT05094258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unicondylar knee prosthesis with mobile insert
Description: Patients with unicondylar knee replacement using the mobile insert option
Study NCT05094258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unicondylar knee prosthesis with fixed insert
Description: Patients with unicondylar knee replacement using the fixed insert option
Study NCT04084275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding education
Study NCT05241145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
Study NCT01088022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant, Palonosetron, Dexamethasone
Description: Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
Study NCT04084275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personal hygiene education
Description: In this training, the puerpera was informed about personal hygiene to prevent infection.